Clinical Trial Detail

NCT ID NCT04047641
Title Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute leukemia

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Quizartinib

Cladribine + Cytarabine + Idarubicin + Quizartinib

Age Groups: senior adult

No variant requirements are available.